ZA201505768B - Respirable agglomerates of porous carrier particles and micronized drug - Google Patents

Respirable agglomerates of porous carrier particles and micronized drug

Info

Publication number
ZA201505768B
ZA201505768B ZA2015/05768A ZA201505768A ZA201505768B ZA 201505768 B ZA201505768 B ZA 201505768B ZA 2015/05768 A ZA2015/05768 A ZA 2015/05768A ZA 201505768 A ZA201505768 A ZA 201505768A ZA 201505768 B ZA201505768 B ZA 201505768B
Authority
ZA
South Africa
Prior art keywords
carrier particles
porous carrier
micronized drug
respirable agglomerates
respirable
Prior art date
Application number
ZA2015/05768A
Other languages
English (en)
Inventor
Jeffry Weers
Patrick Teung
Thomas Tarara
Michael Hartman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA201505768B publication Critical patent/ZA201505768B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2015/05768A 2013-03-14 2015-08-11 Respirable agglomerates of porous carrier particles and micronized drug ZA201505768B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784842P 2013-03-14 2013-03-14
PCT/IB2014/059739 WO2014141135A1 (en) 2013-03-14 2014-03-13 Respirable agglomerates of porous carrier particles and micronized drug

Publications (1)

Publication Number Publication Date
ZA201505768B true ZA201505768B (en) 2017-03-29

Family

ID=50478894

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/05768A ZA201505768B (en) 2013-03-14 2015-08-11 Respirable agglomerates of porous carrier particles and micronized drug

Country Status (22)

Country Link
US (2) US9452139B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968570A1 (cg-RX-API-DMAC7.html)
JP (1) JP6374414B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150129716A (cg-RX-API-DMAC7.html)
CN (1) CN105188757B (cg-RX-API-DMAC7.html)
AU (2) AU2014229265A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015021814A2 (cg-RX-API-DMAC7.html)
CA (1) CA2905615A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015002632A1 (cg-RX-API-DMAC7.html)
EA (1) EA201591729A1 (cg-RX-API-DMAC7.html)
GT (1) GT201500295A (cg-RX-API-DMAC7.html)
HK (1) HK1212616A1 (cg-RX-API-DMAC7.html)
IL (1) IL240963A (cg-RX-API-DMAC7.html)
MA (1) MA38397A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015012814A (cg-RX-API-DMAC7.html)
PE (1) PE20151655A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501882A1 (cg-RX-API-DMAC7.html)
SA (1) SA515361055B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201506397QA (cg-RX-API-DMAC7.html)
TN (1) TN2015000395A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014141135A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201505768B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR20130056244A (ko) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
WO2014118532A1 (en) * 2013-01-31 2014-08-07 Prosonix Limited Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
MX2016012641A (es) * 2014-03-27 2016-12-14 Novartis Ag Dispersiones solidas secas en aceite en agua por aspersion para inhalacion de ingredientes farmaceuticos activos.
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
WO2016142708A2 (en) * 2015-03-10 2016-09-15 Cipla Limited Pharmaceutical composition
US10423736B2 (en) * 2015-08-28 2019-09-24 University Of British Columbia Methods and systems for simulating hydrodynamics in gas-solid fluidized beds
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US20200324064A1 (en) * 2019-04-10 2020-10-15 Cai Gu Huang Inhalation Device for Administering Powdered Pharmaceutical Composition
WO2020247376A1 (en) * 2019-06-03 2020-12-10 Cai Gu Huang Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021030307A1 (en) * 2019-08-15 2021-02-18 Abbott Laboratories Nutritional powder manufacturing process using micronization, and powder composition
US11717517B2 (en) * 2020-04-13 2023-08-08 Universitatsspital Basel LSD dose identification
CN114344285B (zh) * 2020-10-14 2023-11-14 江苏恒瑞医药股份有限公司 改良的可吸入团聚物
CN116546980A (zh) * 2020-12-11 2023-08-04 江苏恒瑞医药股份有限公司 用于肺部递送的药物组合物
CN113318097A (zh) * 2021-04-29 2021-08-31 珠海瑞思普利医药科技有限公司 一种抗特发性肺纤维化的粉雾剂及制备方法
CN116785246A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 一种药物微球及含其的气雾剂
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
NZ243314A (en) 1991-06-26 1994-07-26 Schering Corp Powder dispenser; single metered dose rotated to dispensing conduit
US5829434A (en) 1992-12-18 1998-11-03 Schering Corporation Inhaler for powdered medications
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
HU220472B1 (hu) 1994-09-21 2002-02-28 Inhale Therapeutic Systems Eljárás és készülék por aeroszolosítására, valamint a készülékben alkalmazott adagolócső-egység
ATE209053T1 (de) 1996-01-03 2001-12-15 Glaxo Group Ltd Inhaliervorrichtung
EP0883415B1 (en) 1996-02-21 2002-05-02 Schering Corporation Powdered medication inhaler
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
ES2195121T3 (es) 1996-11-11 2003-12-01 Christian R Noe Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento.
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
KR100813784B1 (ko) 1999-05-28 2008-03-13 넥타르 테라퓨틱스 에어로졸화된 약물의 계량된 양을 투여하는 장치 및 방법
US20010029947A1 (en) 1999-12-17 2001-10-18 Steve Paboojian Receptacles to facilitate the extraction of powders
US7069929B2 (en) 2000-02-01 2006-07-04 Quadrant Technologies Limited Dry powder inhaler
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
WO2004054556A1 (en) 2002-12-13 2004-07-01 Adagit Pharmaceutical porous particles
KR101066788B1 (ko) 2003-04-09 2011-09-21 노바르티스 아게 공기 입구 차폐 부재를 갖춘 에어로졸화 장치
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
PL1718353T3 (pl) 2004-02-24 2020-06-01 Microdose Therapeutx, Inc. Urządzenie do dostarczania leku na bazie strugi syntetycznej
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
WO2008000839A1 (en) 2006-06-30 2008-01-03 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
RU2463085C2 (ru) 2006-10-25 2012-10-10 Новартис Аг Аппарат для распыления порошка, способ его изготовления и применения и его компоненты
RU2497524C2 (ru) 2008-05-15 2013-11-10 Новартис Аг Внутрилегочное введение флуорохинолона
KR101290893B1 (ko) 2009-04-09 2013-07-29 노파르티스 아게 피롤리디늄 염의 제조 방법
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR101730684B1 (ko) 2010-04-01 2017-04-26 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말을 위한 담체 입자 제조 방법
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
PE20151655A1 (es) 2015-11-26
PH12015501882A1 (en) 2015-12-07
SA515361055B1 (ar) 2016-11-13
CA2905615A1 (en) 2014-09-18
AU2017203258A1 (en) 2017-06-08
AU2017203258B2 (en) 2019-06-20
CL2015002632A1 (es) 2016-03-28
US20140302147A1 (en) 2014-10-09
BR112015021814A2 (pt) 2017-07-18
IL240963A (en) 2017-05-29
US9744178B2 (en) 2017-08-29
AU2014229265A1 (en) 2015-09-03
GT201500295A (es) 2017-09-28
EP2968570A1 (en) 2016-01-20
KR20150129716A (ko) 2015-11-20
MA38397A1 (fr) 2018-01-31
HK1212616A1 (zh) 2016-06-17
US9452139B2 (en) 2016-09-27
US20160354388A1 (en) 2016-12-08
JP2016512494A (ja) 2016-04-28
CN105188757A (zh) 2015-12-23
CN105188757B (zh) 2019-04-30
MX2015012814A (es) 2016-02-03
TN2015000395A1 (en) 2017-01-03
WO2014141135A1 (en) 2014-09-18
SG11201506397QA (en) 2015-09-29
IL240963A0 (en) 2015-11-30
EA201591729A1 (ru) 2016-05-31
JP6374414B2 (ja) 2018-08-15

Similar Documents

Publication Publication Date Title
IL240963A (en) Breathing agglomerates of airborne carrier particles and minimized drugs
IL236666B (en) Systems and methods for delivering a drug as a dry powder
IL240291B (en) History of pyridazinone and pharmaceutical preparations containing them
EP3052551A4 (en) Benefit agent containing delivery particle
SG11201600028YA (en) Substituted aminopyrimidine compounds and methods of use
EP3063982A4 (en) User equipment and methods of bearer operation for carrier aggregation
SG11201510179PA (en) Amino-triazine derivatives and pharmaceutical composition containing said derivatives
SG11201505411RA (en) Microdevices for separation of non-spherical particles and applications thereof
EP3053937A4 (en) Modified polytetrafluoroethylene fine powder and uniaxially oriented porous body
ZA201507373B (en) Inhalable pharmaceutical compositions and the inhaler devices containing them
PT3613421T (pt) Ácido acetilsalicílico para reduzir o risco de um evento tromboembólico
EP2964261A4 (en) STABILIZATION OF MOISTURE-SENSITIVE DRUGS
HUE055773T2 (hu) Epinefrin finom részecskék és módszerek azok alkalmazására az epinefrinre reagáló állapotok kezelésében
IL244496A0 (en) Synthesis and particle engineering of co-crystals
PT3470074T (pt) Probióticos
EP3006106A4 (en) Catalyst particles, loaded catalyst particles, and use of same
IL240505A0 (en) Accumulations of lanthanides and methods for their use
GB201806558D0 (en) Superfically porous particles with precisely controlled particle density and methods of preparation and use thereof
IL276838B (en) Oral formulation and suspension of an oncology drug
ZA201507706B (en) Inhalable pharmaceutical compositions and the inhaler devices containing them
IL241070A0 (en) Powder particles with additional coating
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201307659D0 (en) Preparation of drug particles by micronisation
GB201415815D0 (en) Size reduction device and method for the size reduction of solid particles
AU2013205497B2 (en) Dry powder inhaler and methods of use